Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation

Lin Wang, Jian Wang, Bao-En Wang, Pei-Gen Xiao, Yan-Jiang Qiao, Xue-Hai Tan

INTRODUCTION
Hepatic fibrosis is a reversible wound healing response to chronic liver injury due to a variety of insults, including viral hepatitis (especially hepatitis B and C), alcohol abuse, drugs, metabolic diseases, autoimmune attack of hepatocytes or congenital abnormalities[1,2]. As shown in many recent studies, hepatic stellate cells (previously called Ito cells, lipocytes, perisinusoidal cells, or fat-storing cells) are primary cell types to mediate fibrogenesis[1,2]. In normal liver, hepatic stellate cells (HSCs) are nonparenchymal quiescent cells with functions to store vitamin A. Following liver injury of any etiology, HSCs undergo a process of activation, transform from quiescent vitamin A-rich cells to proliferative, fibrogenic, contractile myofibroblasts. Activated HSCs lose lipid droplets, feature high level expression of α-smooth muscle actin (α-SMA), and also are responsible for the deposition of the majority of excess extracellular matrix (ECM, predominantly types I and III collagen), which leads to form action of scar tissue in the fibrotic liver[3-4].

Herbal compound 861 (Cpd 861) is an extract of 10 herbs with *Salvia miltiorrhiza*, *Astragalus membranaceus* and *Spatholobus suberectus* as its chief components. The recipe of this mixed compound was based on the therapeutically indications of Chinese medicine. Clinical studies showed Cpd 861 could significantly improve clinical symptoms in hepatic fibrosis patients as well as the biochemical parameters associated with diseases in clinical tests for patients[5,6]. Experimental research also showed that Cpd 861 could inhibit cell proliferation, reduce the level of α-SMA and reverse the process of liver fibrosis on rat model[7-8]. In this study, we aimed to investigate the effects of Cpd 861 on LX-2 and HepG2 cell proliferation and expression of α-SMA in LX-2 cells.

MATERIALS AND METHODS

**Materials**
Human activated hepatic stellate cell line LX-2 was a gift from Dr. Friedman of Mount Sinai School of Medicine. LX-2 cells were a low-passage human cell line from normal human stellate cells that were spontaneously immortalized[8,9]. The cells exhibited typical features of stellate cells and expressed α-SMA under all culture conditions and were regarded as at least partially activated even after immediate replating. LX-2 cells underwent further activation during growth and expansion on plastic surfaces[9].

Human hepatocellular carcinoma cell line HepG2 was purchased from the Chinese Academy of Medical Sciences (Beijing, China). Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine and streptomycin were purchased from Gibco, Invitrogen, Carlsbad, CA. Fetal bovine serum (FBS) was from Hyclone, USA. Penicillin and phenazine methosulfate (PMS) were from Sigma, USA. MTS and oligo (dT)_15 primers were acquired from Promega, USA. TRIzol reagent and Moloney murine leukemia virus reverse transcriptase (M-MLV RT) were the products of Invitrogen, CA. SYBR Green I was purchased from OPE Technology Development Company, Shanghai, China. Hotstar Taq DNA polymerase was purchased from TW-Biotech, China.

**Materials and Methods**

AIM: To investigate the effects of herbal compound 861 (Cpd 861) on cell proliferation in human hepatic stellate cells (LX-2) and human hepatocellular liver carcinoma cells (HepG2), and expression of α-smooth muscle actin (α-SMA) in LX-2 cells.

METHODS: LX-2 and HepG2 cells were incubated with various concentrations of Cpd 861 (0.1-0.003 mg/mL) for 1, 2, 3, 5 and 7 d. Cell proliferation was analyzed by 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) assay. Effects of Cpd861 on the expression of α-SMA mRNA in LX-2 cells were measured by real-time quantitative PCR method using SYBR Green I technology.

RESULTS: Cpd 861, at 0.1 mg/mL, significantly inhibited LX-2 cell proliferation (15% decrease relative to control, P<0.05) after 3 d of incubation. The inhibitory effects seemed to increase with the treatment time (25% decrease after 5 d of incubation and 35% decrease after 7 d of incubation, P<0.01). However, Cpd 861 did not affect HepG2 cell proliferation at the same concentration used for LX-2 cells. The expression levels of α-SMA mRNA decreased significantly when LX-2 cells were exposed to Cpd 861 for 48 h (59% decrease relative to control, P<0.05) or 72 h (60% decrease relative to control, P<0.01).

CONCLUSION: Cpd 861 can significantly inhibit LX-2 cell proliferation in a dose-dependant manner, and reduce the expression levels of α-SMA mRNA in LX-2 cells. Since hepatic cell proliferation and high level of α-SMA are associated with liver fibrosis, the results suggest that Cpd 861 may be useful in the treatment of this disease.

Wang L, Wang J, Wang BE, Xiao PG, Qiao YJ, Tan XH. Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol 2004; 10 (19): 2831-2835

http://www.wjgnet.com/1007-9327/10/2831.asp
Cell culture and cell proliferation assay

LX-2 cells were cultured in DMEM supplemented with 50 mL/L heat-inactivated FBS, 200 mmol/L L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. HepG2 cells were cultured in DMEM containing 100 mL/L FBS, 200 mmol/L L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin.

MTS assay was used to determine the effect of Cpd 861 on the proliferation of LX-2 and HepG2 cells. In metabolically active cells, MTS was reduced by dehydrogenase enzymes into an aqueous, soluble formazan product. The absorbance was measured directly at 490 nm from 96-well assay plates without additional processing. The quantity of formazan was considered to be directly proportional to the number of viable cells in the culture.

LX-2 and HepG2 cells were seeded into 96-well tissue culture plates containing 100 μL DMEM containing 50 mL/L FBS (5000 LX-2 cells/well and 8000 HepG2 cells/well). After 24 h of incubation (37 °C, 50 mL/L CO2), the medium was carefully removed and 100 μL fresh medium containing various concentrations of Cpd 861 was added into the wells. The cells were treated continuously with Cpd 861 for 1, 2, 3, 5 and 7 d and the medium containing Cpd 861 was changed every other day. At the end of experiments, 20 μL/well of combined MTS/PMS solution was added. After 3 h of incubation at 37 °C in a humidified incubator, the absorbance was analyzed on a VERSAmax microplate reader at 490 nm. Absorbance values were the mean±SE of 3 replicates for each treatment. The cells in only controls and compound controls were included.

RNA isolation and reverse transcription

LX-2 cells were seeded into 60 mm dishes in DMEM containing 50 mL/L FBS. After 3 d of seeding, the medium was carefully removed and fresh medium containing Cpd 861 (0.01 mg/mL) was added. After 24, 48 and 72 h of Cpd 861 treatment, total RNA was extracted from LX-2 cells using TRIzol reagent as the lysis buffer. Complementary DNA (cDNA) was synthesized using oligo (dT)15 primers and M-MLV RT.

Real-time quantitative PCR using SYBR Green I

After the reverse-transcription reaction, cDNA templates were amplified by quantitative real-time PCR. The reaction was performed using the iCyclerIQ real-time PCR detection system (Bio-Rad, USA) with SYBR Green I. Human α-SMA and G3PDH (glyceraldehyde-3-phosphate dehydrogenase) primers were designed using Primer 3 software (Table 1).

Each experiment was performed in 25 μL of reaction volume [1.25 μL of 20× SYBR Green, 1 μL of first strand cDNA (50 ng RNA), 2 μL of each 5 nmol primer, 0.75 U Hotstar Taq DNA polymerase, 2.5 μL of 10x amplification buffer (Mg++ free), 2.5 μL of 25 mmol/L MgCl2, 0.5 μL of 10 mmol/L solution of four dNTP and 15.1 μL of dH2O]. In the last tube, 1 μL of ddH2O was added as a non-template control. The conditions of amplification cycles were as follows: 40 cycles consisting of denaturation at 95 °C for 40 s, annealing at 59 °C (for α-SMA) or at 60 °C (for G3PDH) for 40 s, and extension at 72 °C for 30 s.

The iCycler apparatus was used to measure the fluorescence of each sample in every cycle at the end of the extension. A series of consecutive 10 fold dilution of α-SMA and G3PDH plasmid DNA ranging from 105 copies/μL to 101 copies/μL were used as the templates for the standard curves. The iCycler software was used to construct the calibration curve by plotting the Ct (threshold cycle) vs the logarithm of the number of copies for each calibrator. The number of copies in unknown samples was calculated by comparing their Cts with the standard calibration curve. The quality and quantities of samples were normalized based on that of G3PDH.

After PCR, a melting curve was obtained by increasing the temperature from 55 °C to 95 °C with a temperature transition rate of 0.1 °C/s. The melting curves of all final PCR products were analyzed. The differences in melting temperature of PCR products allowed us to distinguish genuine products from nonspecific products, and primer dimers. To ensure that the correct product was amplified in the reaction, all samples were also separated on 20 g/L agarose gel electrophoresis. All PCR conditions and primers were optimized to produce a single product of the correct basepair size.

Table 1 Oligonucleotide PCR primers for human α-SMA and G3PDH

| Oligonucleotide | Oligonucleotide primer sequence | Fragment size |
|----------------|--------------------------------|---------------|
| α-SMA          |                                 |               |
| sense          | ACT GGG ACG ACA TGG AAA AG      | 265 bp        |
| antisense      | TAG ATG GGG ACA TGG TGG GT      |               |
| G3PDH          |                                 |               |
| sense          | ACC CAG AAG ACT GTG GAT GG      | 125 bp        |
| antisense      | TTC AGC TCA GGG ATG ACC TT      |               |

Statistical analysis

Data were expressed as mean±SE. Statistical analysis was performed using GraphPad Prism (version 3.0) software. The t test was used for comparison between the groups. P<0.05 was considered statistically significant.

RESULTS

Cell proliferation assay

We examined the effects of Cpd 861 on the proliferation of LX-2 and HepG2 cells (Figures 1, 2). Cells were incubated...
with 0.1 mg/mL, 0.03 mg/mL, 0.01 mg/mL and 0.003 mg/mL of Cpd 861 for different days (Figure 1). Cell proliferation was performed by MTS assay. As shown in Figure 2, the effects of Cpd 861 on LX-2 cell proliferation seemed to be correlated with the dose. A significant proliferation inhibition was observed when Cpd 861 concentration was over 0.03 mg/mL (Figure 2). As shown in Figure 1A, 0.1 mg/mL Cpd 861 significantly inhibited LX-2 cell proliferation (15% decrease relative to control, $P<0.05$) after 3 d of incubation. The inhibition effects seemed to increase with the treatment time (25% decrease after 5 d of incubation and 35% decrease after 7 d of incubation, $P<0.01$). The inhibition of cell proliferation Cpd 861 at 0.03 mg/mL concentration was also observed on d 3 (15% decrease relative to control) and on d 5 (21% decrease relative to control) (data not shown), and still could be observed on d 7 (18% decrease relative to control) (Figure 2). However, Cpd 861, at 0.01 mg/mL and 0.003 mg/mL concentrations, did not inhibit LX-2 proliferation evidently. The effects of Cpd 861 on LX-2 cell proliferation seemed low at early time points (on day 1 and day 2). We also examined the effects of Cpd 861 on the proliferation of HepG2 cells. As shown in Figures 1B and 2, Cpd 861 did not affect HepG2 cell proliferation.

**Quantification of expression of α-SMA mRNA in Cpd 861-treated LX-2 cells**

We examined the effect of Cpd 861 on the expression of α-SMA, a phenotypic marker of activated HSCs. The PCR amp/cycle graph and standard curve graph of α-SMA are shown in Figure 3. The standard curve showed a correlation coefficient...
>0.99, indicating a precise log-linear relationship. As shown in melt curve graph (Figure 4), single and sharply defined melting curves with narrow peaks were obtained for PCR products of α-SMA gene. Bands visible after electrophoresis on 2% agarose gel and ethidium bromide staining correlated well with the quantitative PCR results. As shown in Figure 5, Cpd 861 could reduce the expression levels of α-SMA in LX-2 cells after treatment. When LX-2 cells were exposed to Cpd 861 for 48 or 72 h, the expression levels of α-SMA decreased significantly (59% decrease relative to control at 48 h, P<0.05, and 60% decrease relative to control at 72 h, P<0.01) (Figure 5).

**DISCUSSION**

In the liver, activated stellate cells are the key mediators of fibrosis[23]. During hepatic fibrogenesis, HSCs undergo an activation process, becoming highly proliferative and α-SMA positive myofibroblast-like cells.

Cpd 861 is an effective herbal compound for treatment of patients with hepatic fibrosis[24]. Its function to effectively reverse hepatic fibrosis has been confirmed by liver biopsies[25-27]. In other studies, data showed that Cpd 861 also could suppress inflammation and fibrogenesis of the liver tissue[27,31,104] and reduce expression of collagens and fibrosis related cytokines[28,83,105]. It could also inhibit rat hepatic stellate cell proliferation in a dose-dependent manner and decrease activation of rat HSCs in vivo and in vitro[30,31].

Our results suggested that Cpd 861 could significantly inhibit human hepatic stellate cell LX-2 proliferation in a dose-dependent manner when its concentration was over 0.03 mg/mL. The inhibition function increased obviously with concentration, Cpd 861 did not inhibit LX-2 cell proliferation. Additionally, Cpd 861 can reduce the expression levels of α-SMA mRNA in LX-2 cells and this function seems independent of its effects on inhibition of cell proliferation.

**ACKNOWLEDGEMENT**

We thank Dr. Friedman and Mount Sinai, School of Medicine, for their help in providing the LX-2 cell line.

**REFERENCES**

1. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250
2. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-436
3. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451
4. Reeves HL, Friedman SL. Activation of hepatic stellate cells—a key issue in liver fibrosis. Front Biosci 2002; 7: d488-826
5. Wang BE, Wang TL, Jia JD, Ma H, Duan ZP, Li XM, Li J, Wang AM, Qian LX. Experiment and clinical study on inhibition and reversion of liver fibrosis with integrated Chinese and Western Medicine. CJIM 1999; 5: 6-11
6. Yin SS, Wang BE, Wang TL. The effect of Cpd 861 on chronic hepatitis B related fibrosis and early cirrhosis: A randomized, double blind, placebo controlled clinical trial. Zhonghua Ganzangbing Za Zhi 2003; 12: 467-470
7. Wang TL, Wang BE, Zhang HH, Liu X, Duan ZP, Zhang J, Ma H, Li XM, Li NZ. Pathological study of the therapeutic effect on HBV-related liver fibrosis with herbal compound 861. Weichangxingxue He Ganbingxue Za Zhi 1998; 7: 148-153
8. Taim P, Higuchi H, Kocova E, Rippe RA, Friedman SL, Gores GJ. Activated stellate cells express the TRAIL Receptor-2/Death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95
9. Cao Q, Mak KM, Ren C, Lieber CS. Leptin stimulates tissue inhibitor of metalloprotease-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependent MAPK pathways. J Biol Chem 2004; 279: 4292-4304
10. Sutherland MW, Learmonth BA. The tetrazolium dyes MTS and XTT provide new quantitative assays for superoxide and superoxide dismutase. Free Radic Res 1997; 27: 283-289
11. Dunigan DD, Waterb SB, Owen TC. Aqueous soluble tetrazolium/formazan MTS as an indicator of NADPH- and NADPH-dependent dehydrogenase activity. Biotechniques 1995; 19: 640-649
12. Stagliano KE, Carchman E, Deb S. Real-time polymerase chain reaction quantitation of relative expression of genes modulated by p53 using SYBR Green I. Methods Mol Biol 2003; 234: 73-91
13. Zhang FK, Wang BE, Wang TL, Jia JD, Gong Z, Zhang J. Effect of different pharmaceuticals of herbal compound 861 on experimental liver fibrosis. Zhonghua Zhongxi Yi He Za Zhi 2000; 10: 15-16
14. Jia JD, Wang BE, Dong Z, Cui L, Zhu JX, Che JT. The effect of herbal compound 861 on mRNA levels for type I, III, and IV collagen and TGF-β in immune complex rat liver fibrosis. Zhonghua Ganzangbing Za Zhi 1996; 4: 214-216
15. Ma H, Wang BE, Ma XM, Jia JD. Effect of herbal compound
Ding HG, Tang SZ, Wang BE, Jia JD, Zhao CH. Effects of herbal compound 861 in hepatic stellate cell expressing endothelin-1 protein and mRNA. Zhonghua Ganzangbing Zazhi 2003; 11: 308

Yin CH, Ma H, Wang AM, Ma XM, Jia JD, Wang BE. Effect of compound 861 on tissue inhibitor of metalloproteinase 1 gene expression of HSC-T6 cells. Zhonghua Ganzangbing Zazhi 2002; 10: 197-199

Ding HG, Wang BE, Shang HW. Effect of herbal compound 861 on expression and activity of nitric oxide synthase in hepatic stellate cells. Zhonghuo Zhongxiyi Jiehe Zazhi 2002; 22: 362-364

Yin CH, Ma H, Wang AM, Ma XM, Jia JD, Wang BE. Effect of compound 861 on stromelysin gene expression of HSC-T6 cell. Linchuang Ganzangbing Zazhi 2002; 18: 168-170

You H, Wang EN, Wang TL, Ma XM, Zhang J. Proliferation and apoptosis of hepatic stellate cells and effects of compound 861 on liver fibrosis. Zhonghua Ganzangbing Zazhi 2000; 8: 78-80

Ma H, Wang BE, Ma XM, Jia JD. Effect of compound 861 on hepatic stellate cell proliferation and collagen synthesis. Zhongguo Linchuang Yaoleixue Yu Zhiliaoouxue Zazhi 1998; 3: 172-175

Wall SJ, Edwards DR. Quantitative reverse transcription-polymerase chain reaction (RT-PCR): a comparison of primer-dropping, competitive, and real-time RT-PCRs. Anal Biochem 2002; 300: 269–273

Pérez C, Vandesompele J, Vandenbergroucke I, Holtappels G, Speleman F, Gevaert P, Cauwenberge PV, Bachert C. Quantitative real time polymerase chain reaction for measurement of human Interleukin-5 receptor alpha spliced isoforms mRNA. BMC Biotechnol 2003; 3: 17-23

Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 2002; 30: 503-512

Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, Bell SM, Combaret V, Puisieux A, Mighell A, Robinson PA, Inglehearn CF, Isaacs JD, Markham AF. Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003; 3: 18-31

Ramos-Payan R, Aguilar-Medina M, Estrada-Parra S, Gonzalez-Y-Merchand JA, Favila-Castillo L, Monroy-Ostria A, Estrada-Garcia IC. Quantification of cytokine gene expression using an economical real-time polymerase chain reaction method based on SYBR Green I. Scand J Immunol 2003; 57: 439-445

Edited by Kumar M and Wang XL. Proofread by Xu FM